

# Integrated Filing — IndAS

## General information about company

Scrip Code	524654
NSE Symbol	NATCAPSUQ
MSEI Symbol	NOTLISTED
ISIN	INE936B01015
Name of company	Natural Capsules Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	13-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	03-11-2025
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Second quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited
Segment Reporting	Single segment
Description of single segment	Pharmaceutical
Start date and time of board meeting	13-11-2025 14:18:00
End date and time of board meeting	13-11-2025 16:20:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	29-05-2025
Indicate Company website link for updated RPT policy of the Company	www.naturalcapsules.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter	

Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?

No

The Company has not made any default on Loans and Debt Securities.

## Financial Results Ind-AS

Amount in (Lakhs)

	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2025	01-04-2025
B	Date of end of reporting period	30-09-2025	30-09-2025
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
1	<b>Income</b>		
	Revenue from operations	4,458.02	8,882.31
	Other income	172.79	341.87
	<b>Total income</b>	<b>4,630.81</b>	<b>9,224.18</b>
2	<b>Expenses</b>		
(a)	Cost of materials consumed	2,281.76	4,491.81
(b)	Purchases of stock-in-trade	0.00	0.00
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(32.46)	31.51
(d)	Employee benefit expense	370.48	731.79
(e)	Finance costs	145.18	280.94
(f)	Depreciation, depletion and amortisation expense	202.04	401.06
(f)	<b>Other Expenses</b>		
1	Other Expenses	1,294.04	2,569.51
	<b>Total other expenses</b>	<b>1,294.04</b>	<b>2,569.51</b>
	<b>Total expenses</b>	<b>4,261.04</b>	<b>8,506.62</b>
3	<b>Total profit before exceptional items and tax</b>	<b>369.77</b>	<b>717.56</b>
4	Exceptional items	0.00	0.00
5	<b>Total profit before tax</b>	<b>369.77</b>	<b>717.56</b>
6	Tax expense		
7	Current tax	87.51	175.89
8	Deferred tax	1.22	8.33
9	<b>Total tax expenses</b>	<b>88.73</b>	<b>184.22</b>
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00
11	<b>Net Profit Loss for the period from continuing operations</b>	<b>281.04</b>	<b>533.34</b>
12	Profit (loss) from discontinued operations before tax	0.00	0.00
13	Tax expense of discontinued operations	0.00	0.00
14	<b>Net profit (loss) from discontinued operation after tax</b>	<b>0.00</b>	<b>0.00</b>
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00
16	<b>Total profit (loss) for period</b>	<b>281.04</b>	<b>533.34</b>
17	<u>Other comprehensive income net of taxes</u>	0.00	0.00
18	<b>Total Comprehensive Income for the period</b>	<b>281.04</b>	<b>533.34</b>
19	<b>Total profit or loss, attributable to</b>		
	<b>Profit or loss, attributable to owners of parent</b>		

	Total profit or loss, attributable to non-controlling interests		
20	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	Details of equity share capital		
	Paid-up equity share capital	1,034.12	1,034.12
	Face value of equity share capital	10	10
27	Details of debt securities		
22	Reserves excluding revaluation reserve		
23	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	2.72	5.16
	Diluted earnings (loss) per share from continuing operations	2.72	5.16
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	2.72	5.16
	Diluted earnings (loss) per share from continuing and discontinued operations	2.72	5.16
24	Debt equity ratio		
25	Debt service coverage ratio		
26	Interest service coverage ratio		
27	Disclosure of notes on financial results		

## Remarks

Debt equity ratio

Debt service coverage ratio

Interest service coverage ratio

## Statement of Asset and Liabilities

Amount in (Lakhs)

	Particulars	Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	30-09-2025
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
	Assets	
1	Non-current assets	
	Property, plant and equipment	8,897.57
	Capital work-in-progress	30.25
	Investment property	0.00
	Goodwill	0.00

	Other intangible assets	114.33
	Intangible assets under development	0.00
	Biological assets other than bearer plants	0.00
	Investments accounted for using equity method	0.00
	Non-current financial assets	
	Non-current investments	2,274.00
	Trade receivables, non-current	0.00
	Loans, non-current	7,359.44
	Other non-current financial assets	234.39
	Total non-current financial assets	<b>9,867.83</b>
	Deferred tax assets (net)	0.00
	Other non-current assets	5.53
	Total non-current assets	<b>18,915.51</b>
2	Current assets	
	Inventories	2,032.80
	Current financial asset	
	Current investments	0.00
	Trade receivables, current	6,092.64
	Cash and cash equivalents	75.74
	Bank balance other than cash and cash equivalents	204.10
	Loans, current	0.00
	Other current financial assets	0.00
	Total current financial assets	<b>6,372.48</b>
	Current tax assets (net)	0.00
	Other current assets	1,240.46
	Total current assets	<b>9,645.74</b>
3	Non-current assets classified as held for sale	0.00
4	Regulatory deferral account debit balances and related deferred tax Assets	0.00
	Total assets	28,561.25
	Equity and liabilities	
1	Equity	
	Equity attributable to owners of parent	
	Equity share capital	1,034.12
	Other equity	16,211.89
	Total equity attributable to owners of parent	<b>17,246.01</b>
	Non controlling interest	
	Total equity	<b>17,246.01</b>
2	Liabilities	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	2,211.85
	Trade payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	0.00
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0.00
	Total Trade payable	0.00
	Other non-current financial liabilities	86.84
	Total non-current financial liabilities	<b>2,298.69</b>

	Provisions, non-current	57.38
	Deferred tax liabilities (net)	483.53
	Deferred government grants, Non-current	0.00
	Other non-current liabilities	0.00
	<b>Total non-current liabilities</b>	<b>2,839.60</b>
	<b>Current liabilities</b>	
	<b>Current financial liabilities</b>	
	Borrowings, current	3,532.13
	Trade payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	0.00
(B)	Total outstanding dues of creditors other than micro enterprises and small enterprises	4,043.90
	Total Trade payable	4,043.90
	Other current financial liabilities	42.86
	<b>Total current financial liabilities</b>	<b>7,618.89</b>
	Other current liabilities	684.61
	Provisions, current	20.93
	Current tax liabilities (Net)	151.21
	Deferred government grants, Current	0.00
	<b>Total current liabilities</b>	<b>8,475.64</b>
3	Liabilities directly associated with assets in disposal group classified as held for sale	0.00
4	Regulatory deferral account credit balances and related deferred tax liability	0.00
	<b>Total liabilities</b>	<b>11,315.24</b>
	<b>Total equity and liabilities</b>	<b>28,561.25</b>
	Disclosure of notes on assets and liabilities	

#### Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

#### Amount in (Lakhs)

	Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
	Date of start of reporting period	01-07-2025	01-04-2025
	Date of end of reporting period	30-09-2025	30-09-2025
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
1	<b>Segment Revenue (Income)</b>		
	(net sale/income from each segment should be disclosed)		
	Total Segment Revenue		
	Less: Inter segment revenue		
	Revenue from operations		
2	<b>Segment Result</b>		
	Profit (+) / Loss (-) before tax and interest from each segment		
	Total Profit before tax		
	i. Finance cost		
	ii. Other Unallocable Expenditure net off Unallocable income		

	Profit before tax		
3		(Segment Asset - Segment Liabilities)	
		Segment Asset	
	Total Segment Asset		
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4		Segment Liabilities	
		Segment Liabilities	
	Total Segment Liabilities		
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments		

### Other Comprehensive Income

Amount in (Lakhs)

	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd- mm-yyyy)
A	Date of start of reporting period	01-07-2025	01-04-2025
B	Date of end of reporting period	30-09-2025	30-09-2025
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss		
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		
5	Total Other comprehensive income		

### Cash flow statement, indirect

Amount in (Lakhs)

	Particulars	Year ended (dd-mm- yyyy)
A	Date of start of reporting period	01-04-2025
B	Date of end of reporting period	30-09-2025
C	Whether results are audited or unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone
	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	717.56
	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	280.94
	Adjustments for decrease (increase) in inventories	78.59

Adjustments for decrease (increase) in trade receivables, current	5.80
Adjustments for decrease (increase) in trade receivables, non-current	0.00
Adjustments for decrease (increase) in other current assets	(92.19)
Adjustments for decrease (increase) in other non-current assets	(1.37)
Adjustments for other financial assets, non-current	1.93
Adjustments for other financial assets, current	0.00
Adjustments for other bank balances	0.02
Adjustments for increase (decrease) in trade payables, current	473.99
Adjustments for increase (decrease) in trade payables, non-current	0.00
Adjustments for increase (decrease) in other current liabilities	327.09
Adjustments for increase (decrease) in other non-current liabilities	0.00
Adjustments for depreciation and amortisation expense	401.06
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0.00
Adjustments for provisions, current	98.84
Adjustments for provisions, non-current	5.00
Adjustments for other financial liabilities, current	(1.19)
Adjustments for other financial liabilities, non-current	0.00
Adjustments for unrealised foreign exchange losses gains	0.00
Adjustments for dividend income	0.00
Adjustments for interest income	320.64
Adjustments for share-based payments	80.83
Adjustments for fair value losses (gains)	0.00
Adjustments for undistributed profits of associates	0.00
Other adjustments for which cash effects are investing or financing cash flow	0.00
Other adjustments to reconcile profit (loss)	0.00
Other adjustments for non-cash items	32.69
Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0.00
Total adjustments for reconcile profit (loss)	<b>1,371.39</b>
Net cash flows from (used in) operations	<b>2,088.95</b>
Dividends received	0.00
Interest paid	0.00
Interest received	0.00
Income taxes paid (refund)	175.89
Other inflows (outflows) of cash	0.00
Net cash flows from (used in) operating activities	<b>1,913.06</b>
Cash flows from used in investing activities	
Cash flows from losing control of subsidiaries or other businesses	0.00
Cash flows used in obtaining control of subsidiaries or other businesses	0.00
Other cash receipts from sales of equity or debt instruments of other entities	0.00
Other cash payments to acquire equity or debt instruments of other entities	0.00
Other cash receipts from sales of interests in joint ventures	0.00
Other cash payments to acquire interests in joint ventures	0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0.00
Proceeds from sales of property, plant and equipment	0.00
Purchase of property, plant and equipment	627.49
Proceeds from sales of investment property	0.00

Purchase of investment property	0.00
Proceeds from sales of intangible assets	0.00
Purchase of intangible assets	0.00
Proceeds from sales of intangible assets under development	0.00
Purchase of intangible assets under development	0.00
Proceeds from sales of goodwill	0.00
Purchase of goodwill	0.00
Proceeds from biological assets other than bearer plants	0.00
Purchase of biological assets other than bearer plants	0.00
Proceeds from government grants	0.00
Proceeds from sales of other long-term assets	0.00
Purchase of other long-term assets	0.00
Cash advances and loans made to other parties	1,543.83
Cash receipts from repayment of advances and loans made to other parties	0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts	0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0.00
Dividends received	0.00
Interest received	320.64
Income taxes paid (refund)	0.00
Other inflows (outflows) of cash	0.00
Net cash flows from (used in) investing activities	<b>(1,850.68)</b>
Cash flows from used in financing activities	
Proceeds from changes in ownership interests in subsidiaries	0.00
Payments from changes in ownership interests in subsidiaries	0.00
Proceeds from issuing shares	0.00
Proceeds from issuing other equity instruments	0.00
Payments to acquire or redeem entity's shares	0.00
Payments of other equity instruments	0.00
Proceeds from exercise of stock options	0.00
Proceeds from issuing debentures notes bonds etc	0.00
Proceeds from borrowings	243.03
Repayments of borrowings	0.00
Payments of lease liabilities	15.54
Dividends paid	0.00
Interest paid	280.94
Income taxes paid (refund)	0.00
Other inflows (outflows) of cash	0.00
Net cash flows from (used in) financing activities	<b>(53.45)</b>
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	<b>8.93</b>
Effect of exchange rate changes on cash and cash equivalents	
Effect of exchange rate changes on cash and cash equivalents	0.00
Net increase (decrease) in cash and cash equivalents	<b>8.93</b>
Cash and cash equivalents cash flow statement at beginning of period	68.89
Cash and cash equivalents cash flow statement at end of period	<b>77.82</b>



## Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No.	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty		Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Da Au Co Me wh rat wa apj
	Name	PAN	Name	PAN							
1	Natural Capsules Limited	AAACN6209M	Sunil Laxminarayana Mundra	ADVPM5759J	Director	Remuneration			NA	31.20	0.0
2	Natural Capsules Limited	AAACN6209M	Laxminarayan Moondra	ABQPM2191P	Director	Remuneration			NA	20.00	0.0
3	Natural Capsules Limited	AAACN6209M	Sathyanarayana Mundra	ADVPM5763A	Director	Remuneration			NA	24.85	0.0
4	Natural Capsules Limited	AAACN6209M	Sushil Kumar Mundra	ACSPM4710B	Director	Any other transaction	Sitting Fees		NA	0.27	0.0
5	Natural Capsules Limited	AAACN6209M	Jyothi Mundra	AGXPM3106C	Director	Any other transaction	Sitting Fees		NA	0.27	0.0
6	Natural Capsules Limited	AAACN6209M	RK Prasad	AJNPP9480B	CFO	Remuneration			NA	7.75	1.0
7	Natural Capsules Limited	AAACN6209M	Shilpa Burman	CLFPB7203N	CS	Remuneration			NA	0.75	0.4
8	Natural Capsules Limited	AAACN6209M	Natural Biogenex Private Limited	AAHCN1098H	Subsidiary	Loan		5,000.00	NA	1,261.40	1,5
9	Natural Capsules Limited	AAACN6209M	Sonia Organics	ABIFS0783K	Whole Time Director is a partner	Any other transaction	Lease Rental	10.00	NA	3.60	0.9
10	Natural Capsules Limited	AAACN6209M	Balurghat Technologies Limited	AABCB0443J	Director's son in law is a director	Any other transaction	Travel agency related transaction	10.00	NA	0.00	0.0
11	Natural Capsules Limited	AAACN6209M	Natural Phyto Pharma Private Limited	AAGCN2188R	Subsidiary	Advance		10.00	NA	0.00	0.0
12	Natural Capsules Limited	AAACN6209M	Vivek Outsourcing Services Private Limited	AABCV7834R	Director's son in law is a director	Any other transaction	Travel agency related transaction	25.00	NA	5.36	0.8
13	Natural Capsules Limited	AAACN6209M	M/s.Minakshi Enamels	AADFM0101D	Director is a partner	Any other transaction	Job Work	5.00	NA	0.00	0.0
14	Natural Capsules Limited	AAACN6209M	Shrey Mundra	CBHPM1841B	Managing Directors Son	Remuneration			NA	13.00	1.6
15	Natural Biogenex	AAHCN1098H	Sonia Organics	ABIFS0783K	Director is a partner	Any other transaction	Job Work	50.00	NA	0.00	0.0

	Private Limited									
16	Natural Biogenex Private Limited	AAHCN1098H	R K Prasad	AJNPP9480B	CFO	Remuneration		NA	5.05	0.5
17	Natural Biogenex Private Limited	AAHCN1098H	Shilpa Burman	CLFPB7203N	CS	Remuneration		na	0.00	0.1
18	Natural Capsules Limited	AAACN6209M	Pramod Kasat	AAHPK1223A	Director	Any other transaction	Sitting Fees	na	0.81	0.0
19	Natural Capsules Limited	AAACN6209M	SHIRISH GUNDOPANT BELAPURE	ACBPPB8642A	Director	Any other transaction	Sitting Fees	NA	0.68	0.0
20	Natural Biogenex Private Limited	AAHCN1098H	Pranjal Deshmukh	FYNPD3971F	CS	Remuneration		NA	0.98	0.0
21	Natural Capsules Limited	AAACN6209M	Pranjal Deshmukh	FYNPD3971F	CS	Remuneration		NA	2.92	0.0
22	Natural Capsules Limited	AAACN6209M	Tekkar Yashwanth Prabhu	ACAPP6747K	Director	Any other transaction	Sitting Fees	NA	0.81	0.0

Total value of transaction during the reporting period